US biologic R & D for the development of a rapid-response oral influenza vaccine (AOI #6 BTN)
Ended Definitive Contract Awarded Last action
- Contract number
- 75A50121C00008
- Awardee
-
US Biologic, Inc. UEI TBSGX6MQG877
- Awarding agency
-
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services
- Obligated
- $664,774
Award facts
- Opportunity
-
- BARDA's Division of Research, Innovation & Ventures (DRIVe) Easy Broad Agency Announcement Solicitation · BAA20100SOL0002 · Posted Feb 3, 2020
- Contract value 100% obligated
- $664,774.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Memphis, TN 38103, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | -$73,864 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $738,638 |
About this award
US Biologic, Inc. was awarded a $664,774 firm fixed-price definitive contract by the Office of the Assistant Secretary for Preparedness and Response on July 19, 2021, to conduct research and development for a rapid-response oral influenza vaccine under the Beyond the Needle (BTN) initiative. The contract, which was not set aside for small businesses or other designated groups, required performance in Memphis, Tennessee, with an ultimate completion date of February 29, 2024. This R&D effort represents part of the federal government's broader pandemic preparedness and response capabilities, particularly focused on innovative vaccine delivery mechanisms that could enable faster deployment during influenza outbreaks.
The solicitation for this opportunity was posted on February 3, 2020, with an original due date of October 18, 2022, reflecting the extended planning horizon typical for vaccine development initiatives. By developing an oral formulation rather than injectable vaccines, US Biologic's work under this contract supports the Department of Health and Human Services' mission to advance medical countermeasures and strengthen the nation's health security infrastructure. The completion of this R&D contract would contribute to expanded vaccine delivery options and potentially improve pandemic response capabilities.
Quick answers
Who was awarded contract 75A50121C00008?
75A50121C00008 was awarded to US Biologic, Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on July 19, 2021.
How much is contract 75A50121C00008 worth?
The government has obligated $664,774 on 75A50121C00008.
Was contract 75A50121C00008 competed?
The extent of competition for 75A50121C00008 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award